A retrospective study of 176 treatment-naïve eyes with neovascular age-related macular degeneration (nAMD) that had undergone intravitreal aflibercept treatment (2.0 mg, 7–8 times over one year) was performed to correlate the effect of aflibercept on the morphological features of nAMD—subretinal hyper-reflective material (SHRM), pigment epithelial detachment (PED), subretinal fluid (SRF), and intraretinal fluid (IRF)—with visual acuity at baseline and at one year. Spectral-Domain Optical Coherence Tomography (SD-OCT) images and best-corrected visual acuity (BCVA) at baseline and at one year were obtained. The relationship between visual acuity and the presence of morphological features at baseline and at one year was statistically analysed....
PURPOSE: To study the effect of various baseline factors, particularly the type of drug (ranibizumab...
BACKGROUND: Subretinal hyperreflective material (SHRM) is a hyperreflective material seen on optical ...
Purpose: to investigate 1-year visual and anatomic outcomes of intravitreal aflibercept for neovascu...
A retrospective study of 176 treatment-naïve eyes with neovascular age-related macular degeneration ...
Abstract Purpose To investigate the visual and anatom...
PubMedID: 30793798Background: The purpose of this study was to investigate changes in best-corrected...
Objective: To determine the effect of subretinal fluid (SRF) resolution on visual acuity in patients...
Purpose: The aim of this study was to evaluate the association of morphological features of subretin...
PURPOSE To assess the effect of a bimonthly treatment regimen with intravitreal aflibercept on re...
A retrospective chart review of patients with persistent subretinal and/or intraretinal fluid, despi...
PURPOSE: To compare the efficacy of intravitreal aflibercept and ranibizumab on the exudative activi...
To evaluate baseline and treatment factors influencing the response of pigment epithelial detachment...
Purpose: To evaluate individualized intravitreal aflibercept regimens for treatment of neovascular a...
Purpose. - To compare the changes in subfoveal choroidal thickness after intravitreal ranibizumab or...
To report the change in visual acuity and central macular thickness (CMT) following treatment with i...
PURPOSE: To study the effect of various baseline factors, particularly the type of drug (ranibizumab...
BACKGROUND: Subretinal hyperreflective material (SHRM) is a hyperreflective material seen on optical ...
Purpose: to investigate 1-year visual and anatomic outcomes of intravitreal aflibercept for neovascu...
A retrospective study of 176 treatment-naïve eyes with neovascular age-related macular degeneration ...
Abstract Purpose To investigate the visual and anatom...
PubMedID: 30793798Background: The purpose of this study was to investigate changes in best-corrected...
Objective: To determine the effect of subretinal fluid (SRF) resolution on visual acuity in patients...
Purpose: The aim of this study was to evaluate the association of morphological features of subretin...
PURPOSE To assess the effect of a bimonthly treatment regimen with intravitreal aflibercept on re...
A retrospective chart review of patients with persistent subretinal and/or intraretinal fluid, despi...
PURPOSE: To compare the efficacy of intravitreal aflibercept and ranibizumab on the exudative activi...
To evaluate baseline and treatment factors influencing the response of pigment epithelial detachment...
Purpose: To evaluate individualized intravitreal aflibercept regimens for treatment of neovascular a...
Purpose. - To compare the changes in subfoveal choroidal thickness after intravitreal ranibizumab or...
To report the change in visual acuity and central macular thickness (CMT) following treatment with i...
PURPOSE: To study the effect of various baseline factors, particularly the type of drug (ranibizumab...
BACKGROUND: Subretinal hyperreflective material (SHRM) is a hyperreflective material seen on optical ...
Purpose: to investigate 1-year visual and anatomic outcomes of intravitreal aflibercept for neovascu...